Title 4.1 Enfermedad refractaria a tratamiento estándar - Dra. María González Cao.pdf ✅

Enfermedad refractaria a tratamiento estandar Maria Gonzalez Cao Instituto Oncológico Dr Rosell Hospital Universitari Dexeus, Barcelona November 22, 2024
NIVO 77%, IPI-NIVO 69%
Summary background ● PD as the best response: 40% for anti PD-1 Ab (24% for IPI-NIVO) ● After 10 years 77% will have progressed (69% if IPI-NIVO) ● 35% of patients will relapse during adjuvant anti PD1 Ab or into the first 6 months of completing adjuvant treatment
Kluger, JITC 2020 https://www.melanomarisk.org.au/